GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation
Open accessThe DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Abstract
Liraglutide and exenatide are glucagon-like peptide receptor (GLP-1R) agonists used in the treatment of type 2 diabetes. Both molecules have been associated with the development of thyroid C-cell tumors after lifetime exposure in rodents. Previously, it has been reported that these tumors are preceded by increased plasma calcitonin and C-cell hyperplasia. We can now document that the murine C-cell effects are mediated via GLP-1R. Thus, 13 wk of continuous exposure to GLP-1R agonists was associated with marked increases in plasma calcitonin and in the incidence of C-cell hyperplasia in wild-type mice. In contrast, similar effects were not seen in GLP-1R knockout mice. Human C-cell cancer is often caused by activating mutations in the rearranged-during-transfection (RET) protooncogene. We developed an immunohistochemical method to assess RET activation in tissues. Liraglutide dosing to mice was not found to activate RET. Further evaluation of the signaling pathways demonstrated that liraglutide increased ribosomal S6, but not MAPK kinase, phosphorylation. These observations are consistent with effects of GLP-1R agonists on rodent C cells being mediated via mammalian target of rapamycin activation in a RET- and MAPK-independent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pharmacological studies in rodents support an association between the use of GLP-1 RAs and the development of medullary thyroid cancer (MTC) resulting in a black box warning for these agents in patients at risk for this condition.”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
Daub, H., Ulrich Weiss, F., Wallasch, C., & Ullrich, A. (1996) · Nature · doi:10.1038/379557a0 · Cited by 1,476
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,241
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 10×
“Two of these slides were stained by standard techniques with hematoxylin and eosin and immunohistochemistry (IHC) for calcitonin (7) and used for the histopathological diagnosis.”
BackgroundMethodResultInfluentialSelf-citationBuse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
International Union of Pharmacology. XXXV. The Glucagon Receptor Family
Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 506
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 1×
“In situ ligand binding We carried out ISLB on tissue sections as previously reported (7, 23).”
MethodThyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992–2006
Aschebrook-Kilfoy, B., Ward, M. H., Sabra, M. M., & Devesa, S. S. (2011) · Thyroid · doi:10.1089/thy.2010.0021 · Cited by 454
Anatomy and embryology of the laboratory rat
Hebel, R., & Stromberg, M. W. (1986) · Cited by 440
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Parks, M., & Rosebraugh, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001578 · Cited by 275
The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
Powell, D. J., Russell, J. P., Nibu, K., Li, G., Rhee, E. N., Liao, M., Goldstein, M., Keane, W. M., Santoro, M. M., Fusco, A., et al. (1998) · PubMed · Cited by 255
Möhr, U., Dungworth, D. L., & Capen, C. C. (1993) · Medical Entomology and Zoology · Cited by 254
Hegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 1×
“In contrast, calcitonin increases or cellular proliferation was not seen in nonhuman primates (7), and no consistent difference between treatment groups were seen in the clinical program for liraglutide (8).”
BackgroundAsai, N., Murakami, H., Iwashita, T., & Takahashi, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17644 · Cited by 184 · cited 1×
“Phosphorylation, in particular at residue Y1062, is required for coupling to key downstream effectors of RET and for transformation (13, 14).”
BackgroundKwon, G., Marshall, C. A., Pappan, K. L., Remedi, M. S., & McDaniel, M. L. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s225 · Cited by 170
Targeting the RET Pathway in Thyroid Cancer
Wells, S. A., & Santoro, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2742 · Cited by 168
Michiels, F.-M., Chappuis, S., Caillou, B., Pasini, A., Talbot, M., Monier, R., Lenoir, G. M., Feunteun, J., & Billaud, M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3330 · Cited by 140
Akeno-Stuart, N., Croyle, M., Knauf, J. A., Malaguarnera, R., Vitagliano, D., Santoro, M., Stephan, C., Grosios, K., Wartmann, M., Cozens, R. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4605 · Cited by 122
Self-citationcDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line
Ishizaka, Y., Ushijima, T., Sügimura, T., & Nagao, M. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)92335-w · Cited by 104
Acton, D. S., Velthuyzen, D., Lips, C. J. M., & Höppener, J. W. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203648 · Cited by 85
mTOR links incretin signaling to HIF induction in pancreatic beta cells
de Velde, S. V., Hogan, M. F., & Montminy, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114228108 · Cited by 83
Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C. (2011) · Neuroendocrinology · doi:10.1159/000330447 · Cited by 80
Salvatore, D., Melillo, R. M., Monaco, C., Visconti, R., Fenzi, G., Vecchio, G., Fusco, A., & Santoro, M. M. (2001) · PubMed · Cited by 71
Lindfors, P. H., Lindahl, M., Rossi, J., Saarma, M., & Airaksinen, M. S. (2006) · Endocrinology · doi:10.1210/en.2005-1620 · Cited by 50
Ramírez, J. L., Watt, H. L., Rocheville, M., & Kumar, U. (2005) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.02.004 · Cited by 14
Agonist-Induced Desensitization and Endocytosis of G-protein-Coupled Receptors
Tanowitz, M., & von Zastrow, M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00027-9 · Cited by 2
Research works printed but not linked: 3
- DeLellis, 1994, Changes in structure and function of thyroid C-cell, 285
- Botts, 1991, Proliferative lesions of the thyroid and parathyroid glands, E-3, 1
- Boorman, 1996, C-cell hyperplasia, C-cell adenoma, and C-cell carcinoma, thyroid in rats, 262
Cited by
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“GLP-1R agonists are capable of inducing increased calcitonin gene expression and C cell hyperplasia in the thyroid of wild-type, but not the GLP-1R knockout (Glp-1r2/2) mice (Yamada et al., 2008; Madsen et al., 2012).”
BackgroundWang, L., Xu, R., Kaelber, D. C., & Berger, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21305 · Cited by 304
Metadata
- Authors
- Madsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., Vundavalli, S., Nyborg, N. C. B., Bjerre Knudsen, L., Moelck, A. M., & Fagin, J. A.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Memorial Sloan Kettering Cancer Center (US)
- Huntingdon Life Sciences (A.P.), Eye, Suffolk, IP23 7PX, United Kingdom
- Novo Nordisk A/S (L.W.M., C.G., I.S., S.A., L.A., A.S.d.B., N.C.B.N., L.B.K., A.M.M.), Novo Allé, DK-2880, Bagsvaerd, Denmark
- Memorial Sloan-Kettering Cancer Center (J.A.K., K.M., A.B., S.V., J.A.F.), New York, New York 10065
- Corresponding author
- Madsen, Lars Wichmann
- Fagin, James A.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2012-03-01
- Volume
- 153
- Issue
- 3
- Pages
- 1538-1547
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC3281535
- OpenAlex
- W2166969890
- Cited by
- 161
- References
- 29
- Citations by year
- 2026: 27 · 2025: 24 · 2024: 15 · 2023: 5 · 2022: 4 · 2021: 2 · 2020: 12 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 8 · 2015: 11 · 2014: 11 · 2013: 15 · 2012: 6
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrinology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA-72597, R01CA072597)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- GLP-1 receptor agonists, liraglutide, exenatide, RET proto-oncogene, calcitonin, mTOR signaling, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Calcitonin, Female, Immunohistochemistry, Ligands, Male, Models, Genetic, Phosphoproteins, Thyroid Gland, Time Factors, Signal Transduction, Receptors, Glucagon, Mice, Knockout, Proto-Oncogene Proteins c-ret, Mice, Glucagon-Like Peptide 1, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.